-
New Oral Drug May Be Alternative to ESAs for Renal Anemia in Dialysis-Initiating Patients, New Study Shows
Time of Update: 2022-06-18
The study shows that the oral drug Daparodustat is safe and effective, non-inferior to ESAs, and can be used as another powerful tool for intervening renal anemia in patients with initial dialysis² .
Intervention Phase: Patients who successfully pass screening will be randomized 1:1 to Daparodustat and ESAs (darbepoetin alfa) .
-
A review of the research progress of leukemia stem cells in acute T lymphoblastic leukemia
Time of Update: 2022-06-18
At present, with the continuous emergence of research results on the maintenance and proliferation of LSCs in human and mouse T-ALL models, as well as on the key signaling pathways involved in regulating self-renewal, we review the signaling pathways related to leukemia stem cells in T-ALL, and summarize Summarize the roles of these signaling pathways in leukemia progression .
-
CD38 emerges as a key regulator of tumor growth in multiple myeloma
Time of Update: 2022-06-17
Figure 3 CD38 KO cells show elevated OXPHOS Given the differences in tumor growth ability in vivo and in vitro, it remains questionable whether changes in mitochondrial content and metabolic function can give CD38-expressing cells an advantage under hypoxic conditions.
-
Express plans to spend about $1.9 billion to harvest Phase 3 clinical JAK inhibitors, GlaxoSmithKline expands hematology pipeline
Time of Update: 2022-06-17
Sierra Oncology's innovative JAK inhibitor momelotinib recently met all primary and key secondary endpoints in a pivotal Phase 3 clinical trial in patients with myelofibrosis and is expected to submit a regulatory filing in the U.
-
Oral azacitidine may prolong survival in patients with acute myeloid leukemia
Time of Update: 2022-06-17
In the randomized QUAZAR AML-001 phase 3 trial (NCT01757535), oral azacitidine (AZA) significantly prolonged compared with placebo in patients with AML in first remission after induction chemotherapy (≥55 years; with or without subsequent consolidation) treatment; not suitable for hematopoietic stem cell transplantation [HCT]) with a median OS of 9.
-
Guideline Overview Chinese Expert Consensus on the Management of Nervous System Side Effects Related to Chimeric Antigen Receptor T-cell Therapy (2022 Edition)
Time of Update: 2022-06-17
In 2019, the American Society for Transplantation and Cell Therapy (ASTCT) further proposed the concept of "immune effector cell-associated neurotoxicity syndrome (ICANS)", that is, after immunotherapy including CAR-T cells, the patient's endogenous or exogenous Clinical manifestations of a series of neurological abnormalities caused by the activation or participation of sex T cells and/or other immune effector cells .
-
4-year follow-up data of zanubrutinib released!
Time of Update: 2022-06-17
Therefore, some researchers conducted a single-arm, open-label, multicenter, phase I study to explore the safety and preliminary antitumor activity of zanubrutinib in the treatment of Chinese R/R BCM patients .
. In the second part of the study, patients were followed for a median of 30.
-
STTT Huazhong University of Science and Technology Huang Liang/Zhou Jianfeng Discovers Better Potential Treatment for TP53 Altered Aggressive B-Cell Lymphoma
Time of Update: 2022-06-16
In ZUMA-1, axicabtagene ciloleucel (Axi-cel), a first-in-class CD19-targeted CAR (CAR19) T cell product, achieved in r/r aggressive B-NHL following ≥2 lines of systemic therapy An objective response rate (ORR) of 82% and a median overall survival (OS) of greater than 2 years .
-
What is the efficacy of Uproleselan combined with chemotherapy in the treatment of relapsed and refractory acute myeloid leukemia?
Time of Update: 2022-06-16
(PK) and recommended phase 2 dose (RP2D); the expansion phase of the study evaluated uproleselan (RP2D) with salvage chemotherapy in the same R/R AML population, and uproleselan in combination with standard (7+3) first-line AML induction regimens Efficacy in a separate cohort of elderly (≥60 years of age) patients with newly diagnosed AML (Figure 1) .
-
Zhong Ling/Yang Zhenglin Reveals Tumor Heterogeneity Between Different R-ISS Stages in Multiple Myeloma Patients Using Single-Cell Transcriptomics
Time of Update: 2022-06-16
Recently, Yang Zhenglin's research group from Sichuan Provincial People's Hospital published a research paper entitled "Exploring the R-ISS stage-specific regular networks in the progression of Multiple Myeloma at single-cell resolution" in Science China Life Sciences, revealing that multiple myeloma Heterogeneity of tumor regulatory networks between different stages of R-ISS in tumor patients .
-
Pola-R-CHP has better PFS than R-CHOP in newly diagnosed DLBCL
Time of Update: 2022-06-16
In addition, the results of a phase IB/II clinical trial showed that Pola-R-CHP (Pola combined with rituximab, cyclophosphamide, doxorubicin and prednisone) as first-line treatment of DLBCL, the overall response rate of patients (ORR) reached 89%, and the complete remission (CR) rate reached 77% .
-
Authoritative experts commented that YESCARTA® was first approved by the FDA for second-line LBCL treatment, a milestone new progress in CAR-T therapy!
Time of Update: 2022-06-16
The ZUMA-7 study is a randomized, open-label, global, multicenter Phase III clinical study evaluating the safety of Axi-cel or previous second-line standard therapy in adult patients with relapsed or refractory LBCL within 12 months of first-line therapy sex and effectiveness .
-
Professor Wei Xudong: Advances in the treatment of patients with acute lymphoblastic leukemia with TKIs 2021 China Oncology Congress
Time of Update: 2022-06-15
Professor Wei Xudong said that from the research results published in the INCB84344-201 trial in 2021, we can see that after the third-generation TKIs combined with hormones are used in elderly or unfit patients, the 24-week complete hematologic remission (CHR) rate reaches 86.
-
Prof. Sizhou Feng: Clinical application of antifungal drugs in the era of targeted therapy 2021 China Oncology Congress
Time of Update: 2022-06-15
Figure 4 Summary Professor Feng Sizhou finally concluded that hematological malignancies are in the era of targeted therapy, but the treatment and prevention of fungal infections cannot be relaxed.
-
Will "V" save "Emergency"!
Time of Update: 2022-06-14
For example, in the Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of hematological malignancies, class I recommends newly diagnosed patients aged ≥ 60 years.
-
Ponatinib combined with steroid first-line therapy is promising in elderly and unfit patients with Ph+ acute lymphoblastic leukemia
Time of Update: 2022-06-14
Studies have shown that imatinib combined with steroid induction therapy, followed by imatinib combined with chemotherapy and stem cell transplantation (SCT), can achieve an overall survival (OS) rate of 49% and 5-year disease-free survival in adult patients with Ph+ ALL.
-
"Safety Investigator" Sees Bloodborne vs. Restructuring FVIII Safety
Time of Update: 2022-06-14
The use of recombinant FVIII to replace blood-derived FVIII greatly reduces the risk of viral infection and greatly improves the safety of the treatment of hemophilia A patients 6 .
-
【ITP changes because of you】Phase 1
Time of Update: 2022-06-13
"Clinical practice sharing Case 2 Basic information: Gender: Female Age: 52 years old Initial platelet level: 18 × 109/L Hormone incompetence: Hormone ineffective Table 2 Case 2 Follow-up and efficacy evaluation records Note: Hormone and Eltrombopag medication All were once a day (qd) .
-
Prof. Mei Heng: Discussion on coagulation in immunotherapy of hematological tumors 2021 China Oncology Congress
Time of Update: 2022-06-13
For the clinical diagnosis of CARAC, according to the consensus of Chinese experts on coagulation disorders related to CAR-T cell therapy, Professor Mei Heng said that it is necessary to clarify the basic conditions of the patient, including: whether there are high-risk factors, such as high tumor burden, CAR-T cells High-speed amplification, high CRS level; determine the degree of increase in cytokines such as IL-6, and determine whether CRS exists .
-
Prof. Qingyuan Zhang: Advances in the treatment of relapsed and refractory diffuse large B-cell lymphoma 2021 China Oncology Congress
Time of Update: 2022-06-13
The results of a phase Ib/II study of Pola combined with Glofitamab in the treatment of R/R DLBCL showed that the combination therapy achieved ORR of 79.
Mosunetuzumab A phase Ib/II study of Pola combined with Mosunetuzumab in patients with R/R aggressive NHL showed that ORR was 65% in DLBCL patients and 62.
